Literature DB >> 30040001

Diagnosis and Multimodal Treatment of Metastatic Maxillofacial Juvenile Embryonal Rhabdomyosarcoma in a Young Golden Retriever.

Julie Marie Gillem1, Louise Sullivan1, Karin U Sorenmo1.   

Abstract

A 2 yr old male castrated golden retriever was evaluated for a rapidly progressing maxillofacial spindle cell tumor. On examination, an ill-defined left maxillary mass, a 2 cm swelling under the left eye, and an enlarged left mandibular lymph node were noted. The dog was bright and alert but appeared painful upon jaw extension. Cytology from the lymph node revealed metastatic disease. Thoracic radiographs and computed tomography scan revealed pulmonary nodules. Computed tomography of the head and neck revealed a 6.7 × 4.1 × 6.5 cm mass at the rostral aspect of the left zygomatic arch invading the orbit. A second opinion of the biopsy specimen in conjunction with positive immunohistochemical staining for desmin led to a revised diagnosis of rhabdomyosarcoma. Treatment consisted of three doses of palliative radiation therapy, in 8 Gy fractions, and chemotherapy with vincristine, cyclophosphamide, and doxorubicin. A rapid clinical response was noted shortly after treatment initiation; however, the response was temporary, and the dog was euthanized due to widespread metastatic disease and associated clinical signs 74 days after initial therapy. This is one of the first reports describing positive results from multimodal treatment with chemotherapy and radiation therapy of a maxillofacial juvenile rhabdomyosarcoma in the veterinary literature.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30040001     DOI: 10.5326/JAAHA-MS-6662

Source DB:  PubMed          Journal:  J Am Anim Hosp Assoc        ISSN: 0587-2871            Impact factor:   1.023


  1 in total

Review 1.  Metastasis in the wild: investigating metastasis in non-laboratory animals.

Authors:  Bushra Abu-Helil; Louise van der Weyden
Journal:  Clin Exp Metastasis       Date:  2019-02-09       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.